CDXC 4.8: Small Float Biotech backed by Li Ka Shing
In this market where SPEC trades at billions with NO revenue, I like CDXC though I may be early. Yes it's not TSLA, yes Value does not work in this market but
With a tiny market cap of 290 mil and revenue growth at 40% (still early-stage market), I am betting with Li Ka Shing, one of the richest and other top 20 institutions including Blackrock who collectively owns 55% of the stock. Short interest is small at 7%.
The better story is that the stock has been basing for a long time, and technicals are improving. I don't want to wait for breakout then buy as by then I would be paying too much a premium. So good enough for me with the IMPROVING technicals and a largely positive trend, and a real growth story.
investors.chromadex.com/news/news-details/2018/ChromaDex-Announces-Strategic-Partnership-for-Aging-Research-with-Jiangxi-Government-in-China/default.aspx
asia.nikkei.com/Business/Health-Care/Nobel-prizes-highlight-Li-Ka-shing-s-role-in-scientific-research
Top Shareholders
Top 25 shareholders own 54.62% of the company
Ownership Name Shares Current Value Change % Portfolio %
10.49%
Ka-shing Li 6,500,937 31.4m 0% no data
10.29%
Hoi Shuen Chau 6,377,783 30.8m 0% no data
4.53%
BlackRock, Inc. 2,804,544 13.5m -0.81% no data
3.97%
The Vanguard Group, Inc. 2,461,485 11.9m 9.03% no data
3.8%
Li Ka Shing (Global) Foundation, Endowment Arm 2,353,139 11.4m 0% 3.25%
3.11%
Phillip and Patricia Frost Philanthropic Foundation, Inc, Endowment Arm 1,929,542 9.3m 0% 42.91%
2.76%
With a tiny market cap of 290 mil and revenue growth at 40% (still early-stage market), I am betting with Li Ka Shing, one of the richest and other top 20 institutions including Blackrock who collectively owns 55% of the stock. Short interest is small at 7%.
The better story is that the stock has been basing for a long time, and technicals are improving. I don't want to wait for breakout then buy as by then I would be paying too much a premium. So good enough for me with the IMPROVING technicals and a largely positive trend, and a real growth story.
investors.chromadex.com/news/news-details/2018/ChromaDex-Announces-Strategic-Partnership-for-Aging-Research-with-Jiangxi-Government-in-China/default.aspx
asia.nikkei.com/Business/Health-Care/Nobel-prizes-highlight-Li-Ka-shing-s-role-in-scientific-research
Top Shareholders
Top 25 shareholders own 54.62% of the company
Ownership Name Shares Current Value Change % Portfolio %
10.49%
Ka-shing Li 6,500,937 31.4m 0% no data
10.29%
Hoi Shuen Chau 6,377,783 30.8m 0% no data
4.53%
BlackRock, Inc. 2,804,544 13.5m -0.81% no data
3.97%
The Vanguard Group, Inc. 2,461,485 11.9m 9.03% no data
3.8%
Li Ka Shing (Global) Foundation, Endowment Arm 2,353,139 11.4m 0% 3.25%
3.11%
Phillip and Patricia Frost Philanthropic Foundation, Inc, Endowment Arm 1,929,542 9.3m 0% 42.91%
2.76%
إخلاء المسؤولية
لا يُقصد بالمعلومات والمنشورات أن تكون، أو تشكل، أي نصيحة مالية أو استثمارية أو تجارية أو أنواع أخرى من النصائح أو التوصيات المقدمة أو المعتمدة من TradingView. اقرأ المزيد في شروط الاستخدام.